OncoZenge is developing a lozenge that will help millions of people with their oral pain. Our primary indication is oral mucositis, a painful side effect from radiotherapy and chemotherapy.
Targeted pain relief with BupiZenge™
BupiZenge™ is a lozenge crafted to provide local pain relief for patients suffering from Oral Mucositis. Our product alleviates that pain through targeted pain relief.
Solving a large unmet medical need
There is a large unmet medical need for local, safe, and effective pain relief for patients suffering from oral mucositis, as well as other oral pain conditions not well served today.
Based on a safe and effective substance
Bupizenge is built on the well known and researched active substance bupivacaine. Studies has shown that the use of bupivacaine in a lozenge gives significant pain relief within minutes and it lasts for hours.
Significant quality of life improvement
By using BupiZenge™, patients are able to eat and drink painlessly, they can limit or stop their use of addictive opioids and avoid hospitalizations in the more severe cases of Oral Mucositis.
halves the pain
Reduction in mouth pain compared to current treatment*
Prescribing physicians prefer BupiZenge™ **
During a 7 day Clinical Trial*
One step away from going to market
BupiZenge™ has progressed through phase 1 and 2 and have received clear regulatory guidance from European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). Planning is now ongoing for phase 3 with a goal to reach approval in several markets as soon as possible.
Oral mucositis is a painful side effect from radiotherapy and chemotherapy. In som cancers nearly all patients develop oral mucositis. Different cancer types and chemotherapy treatments result in different severities 1-4 on WHO’s toxicity scale.
Dr Pooja Nandwani Patel, Head of Department of Radiation Oncology, Sterling Cancer Hospital
Radiotherapy and chemotherapy act independently in determining acute mucosal toxicity and concurrent RT-CT increases the mucositis grades and incidence almost 4 times more…
Stephen T. Sonis, DMD. DMSc , Professor of Oral Medicine, Harvard
Oral mucositis remains a devastatingly painful complication for many patients being treated with anti-cancer cytotoxic chemo- or radiotherapy…
There is a large, global unmet medical need for relieving oral pain stemming from oral mucositis. Every year more than 18 million people are diagnosed with cancer. Due to an aging population and life style this is growing every year.
people are diagnosed with cancer every year
OncoZenge estimates that the commercial opportunity ranges from $100-800M dollars in North America
OncoZenge estimates that the commercial opportunity ranges from $110-540M dollars in Europe
There are no therapeutic treatments for oral mucositis today and several attempts has failed. In these cases patients are left without any pain relief, ineffective pain relief or opioids. BupiZenge™ has the potential to be the only safe and effective local pain relief for oral pain.
United States is facing a major opioid crises with around 76,000 overdoses due to the use of opioids in 2020. BupiZenge™ can contribute to solving this crisis.
Potential to become the leading treatment for oral pain
Mouth and throat surgery e.g. tonsillectomy
Chronic pain (Burning Mouth Syndrome)
Dry mouth (Sjögren’s Syndrome)
Oral ulcerations (Behcet’s disease)
Oral inflammation (Oral Lichen planus)